Back to search

Article

Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial

2024-10-02

Abstract excerpt

<h4> ABSTRACT </h4> <h4>Background</h4> The randomized, double-blind UNIRAD trial evaluating the addition of 2 years of everolimus to endocrine therapy in patients with high-risk, early luminal breast cancer failed to demonstrate a benefit. We report the subgroup analyses. <h4>Patients and Methods</h4> We randomized 1278 patients in a 1:1 ratio to receive 2 years of placebo or everolimus, added to endocrine therap...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a7d8acc4-49c6-59c9-899b-63e28682253e
DOI
10.1101/2024.10.01.24314713
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trialDOI 10.1101/2024.10.01.24314713
The Value of Oral Selective Estrogen Receptor Degraders in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer after Progression on ≥ 1 Line of Endocrine Therapy: Systematic Review and Meta-analysisSemantic proximity
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.Semantic proximity
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.Semantic proximity
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.Semantic proximity
Estimated absolute benefit of adjuvant endocrine therapy after partial-breast irradiation in hormone receptor-positive early breast cancer: a calibrated competing-risks scenario analysis of randomized-trial dataSemantic proximity
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.Semantic proximity
VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.Semantic proximity
Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Premenopausal Women: Subgroup Analysis From the MONARCH 2 TrialSemantic proximity
Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?Semantic proximity
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.Semantic proximity
Oral SERDs: Transforming the treatment of advanced breast cancer-Insights from EMBER-3.Semantic proximity
Complexities of adjuvant endocrine therapy in young premenopausal women.Semantic proximity
Select a neighboring publication to make it the new centre.